Dow Jones
32.432,08 +194,55 (+0,60%) Nasdaq
11.768,84 -55,12 (-0,47%) Nikkei 225
27.497,45 +20,58 (+0,07%) EUR/USD
1,0818 +0,0014 (+0,1298%) BTC-EUR
24.898,50 -856,51 (-3,33%) CMC Crypto 200
589,59 -17,86 (-2,94%)
Novo Nordisk A/S (0QIU.L)
| Chiusura precedente | N/D |
| Rendimento dall'inizio dell'anno (YTD) | N/D |
| Coefficiente di spesa (netto) | N/D |
| Categoria | N/D |
| Ultimo guadagno in conto di capitale | N/D |
| Rating di MorningStar | N/D |
| Rating di Morningstar (rischio) | N/D |
| Rating di sostenibilità |
| Attività nette | N/D |
| Beta (5 anni mensile) | N/D |
| Rendimento | N/D |
| Rendimento medio 5a | N/D |
| Turnover portafoglio titoli | N/D |
| Ultimo dividendo | N/D |
| Media per la categoria | N/D |
| Data di inizio disponibilità | N/D |
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
- GlobeNewswire
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg an
- GlobeNewswire
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 23 March 2023 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, Chair of the Board of Directors communicated: “We are very pleased with the performance of Novo Nordisk in 2022, where we continued to make progress on our strategic aspirations. Globally, we reached almost 40 million patients, the most ever. As Novo Nordisk celebrates its 100th anniversary in 2023, the need for innovation has never been greater. We will continue
